137 related articles for article (PubMed ID: 27803731)
1. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
Kukulka M; Nudurupati S; Perez MC
Therap Adv Gastroenterol; 2016 Nov; 9(6):759-769. PubMed ID: 27803731
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
Kukulka M; Nudurupati S; Perez MC
Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration.
Kukulka M; Nudurupati S; Perez MC
Clin Exp Gastroenterol; 2017; 10():47-56. PubMed ID: 28255251
[TBL] [Abstract][Full Text] [Related]
4. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
Kukulka M; Eisenberg C; Nudurupati S
Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe.
Kukulka M; Nudurupati S; Perez MC
Clin Exp Gastroenterol; 2018; 11():381-389. PubMed ID: 30323643
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
7. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Stark JG; Engelking D; McMahen R; Sikes C
Postgrad Med; 2016 Sep; 128(7):648-55. PubMed ID: 27488574
[TBL] [Abstract][Full Text] [Related]
8. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects.
Damle B; Duczynski G; Jeffers BW; Crownover P; Coupe A; LaBadie RR
Clin Ther; 2014 Feb; 36(2):236-44. PubMed ID: 24447534
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
12. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Lee RD; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Kukulka M; Wu J; Perez MC
J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
Kukulka M; Nudurupati S; Perez MC
Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
[TBL] [Abstract][Full Text] [Related]
17. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
Weisler RH; Stark JG; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of zonisamide orally dispersible tablet and immediate-release capsule formulations: results from two open-label, randomized-sequence, single-dose, two-period, two-treatment crossover studies in healthy male volunteers.
Maanen Rv; Bentley D
Clin Ther; 2009 Jun; 31(6):1244-55. PubMed ID: 19695391
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults.
Newcorn JH; Stark JG; Adcock S; McMahen R; Sikes C
Clin Ther; 2017 Aug; 39(8):1695-1705. PubMed ID: 28760535
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a New Orally Disintegrating Tablet Formulation of Aripiprazole 15 mg Administered Without Water in Healthy Middle-aged Korean Subjects.
Kim Y; Jeon JY; Chung YC; Kim MG
Clin Ther; 2015 Dec; 37(12):2772-9. PubMed ID: 26546405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
